Does the media prefer LQDA or ETON?

In the previous week, Liquidia had 18 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 30 mentions for Liquidia and 12 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.16 beat Liquidia's score of 0.05 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 9 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Eton Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media prefer LNTH or ETON?

In the previous week, Eton Pharmaceuticals had 1 more articles in the media than Lantheus. MarketBeat recorded 12 mentions for Eton Pharmaceuticals and 11 mentions for Lantheus. Lantheus' average media sentiment score of 0.97 beat Eton Pharmaceuticals' score of 0.16 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media prefer BLTE or ETON?

In the previous week, Eton Pharmaceuticals had 4 more articles in the media than Belite Bio. MarketBeat recorded 12 mentions for Eton Pharmaceuticals and 8 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.36 beat Eton Pharmaceuticals' score of 0.16 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Eton Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to ETON or DFTX?

In the previous week, Definium Therapeutics had 3 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 15 mentions for Definium Therapeutics and 12 mentions for Eton Pharmaceuticals. Definium Therapeutics' average media sentiment score of 0.65 beat Eton Pharmaceuticals' score of 0.16 indicating that Definium Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Definium Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMRX or ETON?

In the previous week, Eton Pharmaceuticals had 6 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 12 mentions for Eton Pharmaceuticals and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.30 beat Eton Pharmaceuticals' score of 0.16 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eton Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Eton Pharmaceuticals (ETON) Competitors

$59.91 -1.57 (-2.55%)

Closing price 04:00 PM Eastern

Extended Trading

$60.58 +0.67 (+1.12%)

As of 06:46 PM Eastern

Compare

ETON vs. LQDA, LNTH, BLTE, DFTX, and AMRX

Should you buy Eton Pharmaceuticals stock or one of its competitors? Eton Pharmaceuticals's main competitors and comparable companies include Liquidia (LQDA), Lantheus (LNTH), Belite Bio (BLTE), Definium Therapeutics (DFTX), and Amneal Pharmaceuticals (AMRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Eton Pharmaceuticals compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Eton Pharmaceuticals (NASDAQ:ETON) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Liquidia has a net margin of 30.74% compared to Eton Pharmaceuticals' net margin of 12.02%. Liquidia's return on equity of 149.65% beat Eton Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Eton Pharmaceuticals	12.02%	40.13%	12.37%

Liquidia currently has a consensus target price of $98.08, indicating a potential upside of 38.05%. Eton Pharmaceuticals has a consensus target price of $67.50, indicating a potential upside of 12.67%. Given Liquidia's stronger consensus rating and higher possible upside, analysts clearly believe Liquidia is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Eton Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Eton Pharmaceuticals has lower revenue, but higher earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	40.17	-$68.92M	$1.37	51.86
Eton Pharmaceuticals	$79.95M	21.42	-$4.60M	$0.38	157.66

In the previous week, Liquidia had 18 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 30 mentions for Liquidia and 12 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.16 beat Liquidia's score of 0.05 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	9 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Liquidia has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Summary

Liquidia beats Eton Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Eton Pharmaceuticals (NASDAQ:ETON) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Lantheus has a net margin of 17.69% compared to Eton Pharmaceuticals' net margin of 12.02%. Eton Pharmaceuticals' return on equity of 40.13% beat Lantheus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Eton Pharmaceuticals	12.02%	40.13%	12.37%

Lantheus has higher revenue and earnings than Eton Pharmaceuticals. Lantheus is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.24	$233.56M	$4.14	24.21
Eton Pharmaceuticals	$79.95M	21.42	-$4.60M	$0.38	157.66

Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

Lantheus presently has a consensus price target of $108.11, indicating a potential upside of 7.85%. Eton Pharmaceuticals has a consensus price target of $67.50, indicating a potential upside of 12.67%. Given Eton Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eton Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Eton Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Eton Pharmaceuticals had 1 more articles in the media than Lantheus. MarketBeat recorded 12 mentions for Eton Pharmaceuticals and 11 mentions for Lantheus. Lantheus' average media sentiment score of 0.97 beat Eton Pharmaceuticals' score of 0.16 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eton Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Eton Pharmaceuticals beats Lantheus on 8 of the 15 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Eton Pharmaceuticals (NASDAQ:ETON) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Eton Pharmaceuticals has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Eton Pharmaceuticals	$79.95M	21.42	-$4.60M	$0.38	157.66

In the previous week, Eton Pharmaceuticals had 4 more articles in the media than Belite Bio. MarketBeat recorded 12 mentions for Eton Pharmaceuticals and 8 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.36 beat Eton Pharmaceuticals' score of 0.16 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Belite Bio has a beta of -1.22, meaning that its stock price is 222% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Eton Pharmaceuticals has a net margin of 12.02% compared to Belite Bio's net margin of 0.00%. Eton Pharmaceuticals' return on equity of 40.13% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Eton Pharmaceuticals	12.02%	40.13%	12.37%

Belite Bio currently has a consensus target price of $205.80, suggesting a potential upside of 27.08%. Eton Pharmaceuticals has a consensus target price of $67.50, suggesting a potential upside of 12.67%. Given Belite Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Belite Bio is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Eton Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Eton Pharmaceuticals beats Belite Bio on 10 of the 14 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Definium Therapeutics?

Eton Pharmaceuticals (NASDAQ:ETON) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Eton Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market.

Eton Pharmaceuticals has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	21.42	-$4.60M	$0.38	157.66
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Definium Therapeutics had 3 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 15 mentions for Definium Therapeutics and 12 mentions for Eton Pharmaceuticals. Definium Therapeutics' average media sentiment score of 0.65 beat Eton Pharmaceuticals' score of 0.16 indicating that Definium Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Definium Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals currently has a consensus price target of $67.50, indicating a potential upside of 12.67%. Definium Therapeutics has a consensus price target of $63.00, indicating a potential upside of 38.77%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Definium Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00

Eton Pharmaceuticals has a net margin of 12.02% compared to Definium Therapeutics' net margin of 0.00%. Eton Pharmaceuticals' return on equity of 40.13% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	12.02%	40.13%	12.37%
Definium Therapeutics	N/A	-84.01%	-63.66%

Summary

Definium Therapeutics beats Eton Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Eton Pharmaceuticals (NASDAQ:ETON) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

Eton Pharmaceuticals has a net margin of 12.02% compared to Amneal Pharmaceuticals' net margin of 5.05%. Eton Pharmaceuticals' return on equity of 40.13% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Eton Pharmaceuticals	12.02%	40.13%	12.37%

Amneal Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than Eton Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.89	$72.06M	$0.49	36.53
Eton Pharmaceuticals	$79.95M	21.42	-$4.60M	$0.38	157.66

In the previous week, Eton Pharmaceuticals had 6 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 12 mentions for Eton Pharmaceuticals and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.30 beat Eton Pharmaceuticals' score of 0.16 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Amneal Pharmaceuticals currently has a consensus price target of $17.67, indicating a potential downside of 1.30%. Eton Pharmaceuticals has a consensus price target of $67.50, indicating a potential upside of 12.67%. Given Eton Pharmaceuticals' higher probable upside, analysts clearly believe Eton Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Eton Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Amneal Pharmaceuticals beats Eton Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Eton Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ETON vs. The Competition

Export

Metric	Eton Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.76B	$12.36B	$7.22B	$12.76B
Dividend Yield	N/A	2.66%	2.55%	10.29%
P/E Ratio	157.66	779.68	269.18	24.05
Price / Sales	21.42	760.82	620.68	97.58
Price / Cash	11,861.40	96.52	78.23	52.73
Price / Book	36.75	11.87	13.06	6.16
Net Income	-$4.60M	$2.80B	$3.46B	$347.49M
7 Day Performance	46.84%	1.02%	1.43%	-0.64%
1 Month Performance	45.87%	2.47%	4.58%	2.12%
1 Year Performance	261.99%	7.82%	27.60%	20.16%

Eton Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ETON Eton Pharmaceuticals	3.3944 of 5 stars	$59.91 -2.6%	$67.50 +12.7%	+279.5%	$1.76B	$79.95M	157.66	20	Earnings Report
LQDA Liquidia	4.355 of 5 stars	$74.29 -4.4%	$98.08 +32.0%	+177.9%	$6.64B	$450.91M	54.11	50	Insider Trade Analyst Revision Gap Down
LNTH Lantheus	3.6475 of 5 stars	$100.73 -0.2%	$108.11 +7.3%	+82.2%	$6.58B	$1.54B	24.34	1,193	Positive News Analyst Downgrade
BLTE Belite Bio	3.7569 of 5 stars	$163.59 +0.5%	$205.80 +25.8%	+172.7%	$6.53B	N/A	N/A	10	Analyst Downgrade
DFTX Definium Therapeutics	3.1139 of 5 stars	$45.10 -0.4%	$63.00 +39.7%	+388.0%	$6.06B	N/A	N/A	40	Analyst Forecast Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ETON) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eton Pharmaceuticals (ETON) Competitors

ETON vs. LQDA, LNTH, BLTE, DFTX, and AMRX

How does Eton Pharmaceuticals compare to Liquidia?

Summary

How does Eton Pharmaceuticals compare to Lantheus?

Summary

How does Eton Pharmaceuticals compare to Belite Bio?

Summary

How does Eton Pharmaceuticals compare to Definium Therapeutics?

Summary

How does Eton Pharmaceuticals compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eton Pharmaceuticals (ETON) Competitors

ETON vs. LQDA, LNTH, BLTE, DFTX, and AMRX

How does Eton Pharmaceuticals compare to Liquidia?

Is LQDA or ETON more profitable?

Do analysts recommend LQDA or ETON?

Do institutionals & insiders believe in LQDA or ETON?

Which has better earnings & valuation, LQDA or ETON?

Does the media prefer LQDA or ETON?

Which has more volatility & risk, LQDA or ETON?

Summary

How does Eton Pharmaceuticals compare to Lantheus?

Is LNTH or ETON more profitable?

Which has higher earnings & valuation, LNTH or ETON?

Which has more risk & volatility, LNTH or ETON?

Do analysts prefer LNTH or ETON?

Do institutionals & insiders have more ownership in LNTH or ETON?

Does the media prefer LNTH or ETON?

Summary

How does Eton Pharmaceuticals compare to Belite Bio?

Which has stronger earnings & valuation, BLTE or ETON?

Does the media prefer BLTE or ETON?

Do institutionals and insiders have more ownership in BLTE or ETON?

Which has more risk & volatility, BLTE or ETON?

Is BLTE or ETON more profitable?

Do analysts rate BLTE or ETON?

Summary

How does Eton Pharmaceuticals compare to Definium Therapeutics?

Which has more volatility & risk, ETON or DFTX?

Which has preferable earnings & valuation, ETON or DFTX?

Do insiders and institutionals have more ownership in ETON or DFTX?

Does the media refer more to ETON or DFTX?

Do analysts recommend ETON or DFTX?

Is ETON or DFTX more profitable?

Summary

How does Eton Pharmaceuticals compare to Amneal Pharmaceuticals?

Is AMRX or ETON more profitable?

Which has more risk & volatility, AMRX or ETON?

Which has better valuation and earnings, AMRX or ETON?

Does the media prefer AMRX or ETON?

Do insiders and institutionals have more ownership in AMRX or ETON?

Do analysts recommend AMRX or ETON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools